Emergence of the concept of platelet reactivity monitoring of response to thienopyridines

L. Bonello, A. De Labriolle, M. Scheinowitz, G. Lemesle, P. Roy, D. H. Steinberg, T. L. Pinto Slottow, R. Pakala, A. D. Pichard, P. Barragan, L. Camoin-Jau, F. Dignat-George, F. Paganelli, R. Waksman

Research output: Contribution to journalReview articlepeer-review


Clinical trials have demonstrated the beneficial impact of clopidogrel in preventing major adverse cardiovascular events (MACE), particularly in patients undergoing percutaneous coronary intervention (PCI). The concept of biological clopidogrel resistance emerged with the finding of persistent platelet activation despite clopidogrel therapy in some patients. Further, a link between biological clopidogrel resistance and thrombotic recurrence after PCI was observed and a threshold of platelet reactivity (PR) for thrombotic events was suggested. Consistently, in recent trials, enhanced PR inhibition translated into a reduction in the rate of MACE after PCI. This review aims to present the emergence of the concept of PR monitoring in patients undergoing PCI following recent advances in this field.

Original languageEnglish
Pages (from-to)1214-1219
Number of pages6
Issue number15
StatePublished - Aug 2009
Externally publishedYes


Dive into the research topics of 'Emergence of the concept of platelet reactivity monitoring of response to thienopyridines'. Together they form a unique fingerprint.

Cite this